Received: 18 August 2022
Accepted: 25 November 2022
First Online: 2 December 2022
: All subjects provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Clinical Research Ethics Board, University of British Columbia with approval number #H09-02046.
: Not applicable.
: Ali Guermazi is President of Boston Imaging Core Lab, LLC, and consultant to AstraZeneca, TissueGene, Roche, Galapagos, Merck Serono and Pfizer. Savvas Nicolaou is a subcontractor for a non-drug, clinical study through Massachusetts General Hospital (Horizon Therapeutics), is involved in a research agreement between Siemens Canada and the University of British Columbia, and holds an equity position in Canada Diagnostic Centres. No other authors have competing interests to declare.